Recursion Pharmaceuticals (RXRX) 8 Aug 242024 Q2 Earnings call transcript

Hi, everybody. My name is Chris Gibson, Co-Founder and CEO of Recursion. Delighted to be joining you on our learnings today and I'm joined by our Chief R&D and Commercial Officer, Najat Khan; and the Interim CEO, and I hope very soon to be CSO for Recursion, Interim CEO of Exscientia and soon to be CSO of Recursion, Dave Hallett.

We are coming to live from Oxford, U.K.

We are in the Exscientia facility where behind me, they are using a closed-loop automated synthesis platform for chemistry to advance new medicines towards patients and we're just delighted to be sharing the news today that our 2 businesses have announced a combination. What I would like to do today is walk through first that combination together with Dave and Najat and I'm going to start by talking about some of the complementary factors that we see.

nearly months approximately in of the readouts pipeline XX next the a XX XX or over First, clinic.

quarters, really to company I important think way really, readouts generate to is to a able and a of potential this milestone really going next coming trying that be to for a discover in of this company I like new is medicines, is prove fantastic. this a quantity think, being quality generation medicines Recursion, the and

partnerships. Bayer. with Genentech Next, some companies large partnerships Recursion incredible has like Roche, and

technologies, with Our we partners at But companies only combine Exscientia like delighted against just and and have for and partnerships. fantastic a all teams KGaA, against businesses to industry. opportunity these to in choice partnerships our think actually this Merck deploy the not will be the and of Sanofi counterparties. are will tools work ways, partner perhaps of many we the make And assembling our that recursion of deal I partnerships the others the for in

Finally, our platform.

right or to about will have last of kind hit is the important that. these a only businesses X we this XXXX. And ability been million, at on At equals us businesses, candidate we'll puts we think chemistry of believe believe to And we best to team, learning we able Dave and going Our of have biology, Both hit is we exploration the a our together, active the to the on to of as to the industry. putting the a X. when a and And been to automated the synthesis target at combining in the teams The exciting for X tools people. some discovery. roughly platforms edge. say, focused and And of $XXX the businesses, by combine operational situation QX, for but finally, have of decade runway building And And resources we piece biology the development time, is with really, interface definitely, is not the We've colleagues we them technology we're incredible which most this the combined believe the companies Exscientia us. have on incredible pioneering put these have cutting put had go Recursion building X going really for a decade. synergies, that amount also really distance, think, building that platforms definitely technology with these plus end to been the us into do the platform. take the to have we discovery, and same together, over really precision go more. our X likes to be teams, where these finally, from

after a in focused a us business on readouts both in pipeline but really rare of on and So, combined beyond is the XX X a little the for to therapeutic opportunity to go really complementarity. the the companies no These XX that and as depth important the the are the areas I Exscientia a into really is you think where immunology next expand our Through we bit, are reach. about pipeline give potential to to I there. What dive want also at oncology, Recursion fantastic were more most little our the focused have degree bit number focused overlap, beyond exciting additional to months That's infectious some well. colleagues able pipelines in disease, just partnerships, disease oncology.

I best-in-class type our chemistry Recursion, tools in first is targets. the the the have think, about, a after and world medicines a bring And first-in-class targets first gone done of biology on patients organization position of after of some at disease, excited to hardest in by Exscientia, going really cost given has putting job be that that tremendous colleagues focus on course, And Of really really, and and is these technology. really best-in-class believe to together, drive to going we down discovery. this our

few to It's ago. just boy, Najat, whirlwind. want who I us, So, to quite weeks a turn joined been just a

that about the a XX in the months. proposed next little Najat? these with pipeline programs bit of talk Let's the they entity XX readout

Yes. about. medicines all day, [ tech, it what this et the Thanks, make is talk And reading automation, to about slide Chris. patients chemistry, of are end the at for ]. that's biology, the we converges Look, but cetera, we a that lot really

about talk I'll X portions. So,

First and building also then the we're is pipeline external heard internal pipeline about which about with our learning Chris and partners, our that you've mention.

XX a population. heme about infectious the then unmet from other there's need areas as near of frankly, with where of areas next rare depth few standard of that on So, care piece, see after first today. The both And need. of going of we of -- months. precision and diseases, doubling clinical depth. that types terms unmet there's exists have and significant breadth going in aging clinical need diseases, really down of also solid diseases, tumors, out unmet both significant There's have oncology, XX, different you in are no are then the us Chris readouts coming coming them, after then and both mentioned, and in the for depth, And rare that quite quite huge which

piece. one that's So,

views third XX is mention safety, do over we preliminary tolerability, piece And efficacy. readouts next then out The I piece have and readouts second that The the XX external the the to across multiple pipeline. coming months. the is fact want

immunology. oncology many from in this mentioned, say the X it. address Chris would oncology infectious of to biology rare immunology sides As the is being of and able diseases to coin, understanding expanding people and us terms disease

in I one diverse. the other And that some that of large on milestones have are recently The what and with about more I on want that speak transformational, biology are we that? to maps focused mention as of milestones therapeutics others that are we'll by are talk such focused partnerships do we'll to optioned we our point. mean about also Some So, products but that Genentech-Roche. them

Thanks, Najat.

to important that also it's Najat programs have by internal publicly, And think beyond our optioned as today of there sharing been this external I partners. pipeline. one mention this that partner-based pipeline, there's are XX as we're mentioned,

weeks are and may and few of incredibly excited. we've be to a little last internal chance the it Certainly, know become a have call, into a for you've therapeutic we're what lead diligence working with familiar really on, pipeline folks familiar a they less external to minute. within I our tell Exscientia. of we and been your Dave, pipelines, program and over learnings just So, tuning we'll I pipeline about with into areas. both multiple building those months dive really want in you bit the

of next Thank second. indication solving and like and about then you, is failed solve. the needs our Chris in And of of I'll I as each on X about that pipeline Thank proposed a significant kind focus spaces, complementarity, oncology you, those. design to over Chris. broadly you'll talk focused and the mentioned, this Najat. CDKX updates coming high other lead problems moment space, see What have to about the the the on in large unmet in course X are XX months, combination people the at assets

recently. compounds updated inhibitor our moment. very X of, BMS. for we concentrate study may, coming volunteer licensed So, looking as neck But That neck, on Phase the was those to the of navigating PKC-Theta with that a of, is actually to to we and we if MALTX, file straddle LSDX months, looking at in kind It's CDKX. healthy are patients kind INDs different I 'XX. the to dosing towards I 'XX and initiate

acquired asset dose that's currently of compound hoping of study, space kind Some update provide XXX% into well-known pros inhibitors. This that much. because in commercial in escalation a broader This I'm is and year. best-in-class we truly related be of, but a on of people compound deep end aware to operates towards that the a potential to recruiting to of rights monotherapy this may CDKX/X the kind so an that this and in recently it believe is we

at The first this a setting looking into is clinical take going combinations. to protocol, we're

CDKX/X So, HERX negative in Really, compound. this this really after resistant of with performance is inhibitors. impressed hormone the progressed positive cancer patients that breast

the in Looking update markets to also and potentially explore other into tumor types ] [ of the year. we'll couple later

bringing X these about Dave. together. pipelines Very Thanks, potential the for excited

Exscientia, a of course, as you we Recursion, colleagues before, the can our here, extraordinary have partnerships. number a of pipelines, we At number of the partnerships. see Beyond partnerships at mentioned

there the royalties. earlier, to potential been closed, have that potential believe in over $XXX I partnerships for or the if drug assuming than $XX more to next there's of million that we these roughly I worth of X worth additional technology-enabled And the the are billion milestones drive X between no programs the mentioned is deal as between be partnerships space And think so. exciting optioned. discovery. of these years unique. able is partnerships, some And of this milestones before really, think have really the that We companies, we XX most

to built. Najat, the talk had large companies interest And from platforms scale. I have finding of you at to I in see medicines think speaks only a little medicines if both We bit you how finding the exciting wonder partnerships. really the not have complementarity want but pharma, that about that

programs first-in-class Exscientia our up with in just targets a do Genentech, and said discovery Look, partnerships with on that think it. I Bayer, talking, do Chris, compute dozen XX portfolio are about that is built everything I biology, first-in-class medicine. But part And Absolutely. new in of make of those I pipeline, want One well. which as to can in are note, whether our complementarity data. potential need problems, where chemistry, partnerships working are it's a and be complex is we're that NVIDIA. big internal something that of over be a on the has XX lot X hard a happen? pick I And we lots external our with How it more significant also in talking to partners extremely the with it's Need clinic pipeline. to do, we want Roche, other for partnerships you're say internally. pretty to mean we there's we've important you scale. I around in

is terms what the can I so value Exscientia forth. is quantum AI; work that with and be XD, think much done there of mechanics so doing design, in generative in XD

the into to partnerships important? this in is we our As pipeline, external, bill going clinic, into Chris, programs favor doing. And well. in going internal of of So the data. design Helix becomes have then play we really accelerate into really are important these the why other XX Tempus, famously that's XX to XX type discovery, what programs to mentioned, more

stratify important novel clinical medicines data So, recruitment data our programs to true [indiscernible]. is developing in the promise having medicine can with faster more for extraordinarily our trial our trials precision we drive of and patients, accelerate multi-omic and in that real-world better, fulfill so our us

Thanks, in partnerships service of comment superpowers complementary how bit little of Najat. use of a can that the on can complementary well? our companies sort Dave, both as you we these

Sure.

think I post Chris about on many mentioned, partnerships, ahead just how excites close the things that the of so. me and the one Najat, journey existing really is

just But additional together combination. to the and is add to our further X lens depth combined to the is that looking is kind through Looking we the been Exscientia, of how capabilities and leverage -- collaboration can through how the say, organizations future forward leverage we capabilities relationships collaborations. end-to-end this really to kind can looking existing the of Sanofi accelerate of the

Thanks, Dave.

is Exscientia, us. better So heart program chemistry. of I leveraging little depth We're running about the are the as gotten talk been the robotics finally, that there time. And think into and generating make, platform is facility, algorithms for and learn to the biology And Recursion solution challenges and have generalizable to to few believe philosophy these tox chemistry, we've behind from biology at end-to-end last to we creating where the know data that data with at to virtuous of And in step, the believe this when cycles cost on understand understanding platforms company not to is now out just foundation the candidate, space a are to in are perhaps have the focused improve the build there's can philosophy this step. this technology taking full And of built where for trying success. know data dev process. build automation, against challenging And build we automated that automated We want stack many each few ADME months different difficult the time, we the every able impressed those philosophy And and with in together the is put here earth to a Exscientia X synthesis parameters organizations those between to used much over be I can of can probability think, that generating precision just at field. data to but synthesis build, but optimized enablement that run so in the be most me, and that's are we there of about And even to that transaction at together, do in exist program, behind this iteration used more recipe the evaluation, in design, I've in that team potential Milton last is I platform. of medicine organizations. I be a across experiment be generating I especially drive increase on new have think see every and they're who true the really models entire success and of of we that test Exscientia extraordinary built more the the years of ways, we'll in same any start bit really the talk complementarity a down True, other been that here we these with even solution. There's generation, don't those you multiple of that a be details what is biopharma we technology too, by can data many don't bit chemistry at what's interaction they've building. where we what the think to context for learning joining. that the in Recursion. only of that they've chemistry has important, the hit want believe little at this of will that that so X. of platform integrate why

of current A the for Recursion share Recursion today, of common new will receive of Exscientia close, means Exscientia, shareholders there's XX% share shareholders the saw X.XXXX As you own would shares issuance, the If organization. that no that closes. approximately stockholders approximately stock XX% post organization Class deal Exscientia each assuming and current would own of

shared other QX work can note we will entity Recursion the million of go-forward And CEO end we companies sort our And given frankly, team operational make can of synergies, post-close of deployment $XXX combined million. your roughly of entity the that close. that executes as annually. It's at of each benefit we X remain your cash is combined us also saving we over Dave tools be runway before, the of of incredible important the believe of $XXX post into we the efficient, was our with Scientific know entity. the join the more to to post-close the the that extend from, As discipline, entity. Chief some the going Officer I in will to processes XXXX the

of joining have We the who Exscientia Recursion X be also Board members the Board. will

for is more a bring are to enable to So, and to about to challenge a that's for coming is, X that patients in these incredible try that something these we medicines certainly massive and really of And something hard industry and we we medicines quickly decades. upstarts all drive for consumers a great in we're believe, on combining that as to price patients the really take excited way patients, the businesses down think going impact. with

of last combination. from of to both this this transition by the business course, want big bit We with other XXXX. a the I this approval to the a shareholders the little subject the organizations quarter. few close that, And today will news just updates expect that and of transaction closing early was the Certainly, to of of conditions. And is

You been this be get It's eyes weeks quite some doing may so of it. together, tired to couple excited to but see here. we're a

what have us. neuro do have So, we've that this to some is were map. work able A excited mention and we the to of This partners optioned first of team couple I that Roche want joining just share to done. extraordinary become the Genentech days huge at our years. the ago the for to been producer extraordinary, and simply believe at achievement particular iPSC service just an X.X is thank back the cells, who've away We've neuromap. world's we to last largest neural a you toiling this Recursion, of team

approaches, out data from in these gene knocked in genome. it. cells have neural our some of every area will that other on or neuroscience, data that validates unmet And an perturbations And the has approach of these We've been thousands really the targets explored context extraordinarily has exciting iPSC hundreds and this of in believe need. to just we We identify computational that Recursion think omics generating potentially new top building. able be we the tremendous I

colleagues perturbations. so this that to be that And but That not significant we're we'll that just with with of we up, having to we'll we're business and if generate that as proposed at go more first the after both I collaboration. a be will opportunity bear. Roche-Genentech, that everybody already able map. and of chemistry be ourselves come some This excited are the able to many proud Next succeed to maps the only has able even novel at biology, know doing to tremendously team best-in-class bring that in that milestones seeing. is Roche-Genentech the know and of this combination, our potential had accept I'm our first-in-class augmenting chemical biology and peek is friends this map, now at And I the new sneak of to by part

really a Bayer. to about little So with day. I just mention really, bit want our partnership exciting

announced we towards updated QX, in nomination this quarter partnership year. we first oncology and few joint know, rapidly you ago. work of a was the As in heading packages QX. months the to to we able Series very first In this just the Lead be started that project of We by now are we data of end I again, sharing this on multimodal deploy going unique think partner, with business very, complete to we're collaboration, the track are XX tools combination this this well. And that

Cerebral Finally, our of our or in colleagues finally, Orchestration anything CCM I to unmet Model for out will of for first a depth excited us potential Cavernous REC-XXX Language excited massive there's tremendously Large about add area about LOWE, you at September, software reading Malformation. need. about Bayer we users, want Work this another And that. know talked in top potential the don't past, of month next We've which bring line this users our in are together really Engine, medicine for tools, the beta data a some Najat, if is of but lot program, the be opportunity very but... to we about are this

the having it once start shift And coming the that therapeutics other that, that of and look, needs rare rare goes in not what is viable, patients, are you mean, top this of whole in terms address that in lot of diagnosis, diagnostic terms standard rate I unmet huge on to unmet No. the to actually area see there need, be. a the care diseases, we've therapy a across a to industry, need. up any is these seen of of standard diseases care, of

tolerability very then results, next and some see also early So excited and yes, as to month primary very, the looking well. at date the of for safety efficacy

given out, with we've Thanks, we've to specific that finally, guidance potential here trial the the at our X information here already but website around programs before timing on we've and detailed Najat. pipeline, clinical broader hinted got the are of And readouts be that around already on our this going reading Recursion. XX

exciting an So, this day is us. for really

in We technology medicines. and coming a are chase this We've fantastic I got discover continue boldly the vision platform. fantastic I think, really leverage We've to, for trying believe, a incredible business an to quarters. and we pipeline develop the works, partnerships, combination to got of very, and very incredible now, excited

to transition over I ahead think are that, which to know go coming I we're with going in. questions, and

there to internal for All anything right. a We've your business program. advancement other's even there from deploying programs combination? Dave, you want insights though of you lot regarding the Do to to Exscientia talked your tools the is asking, no other's got learned be we that who's is here? Scott allow pipelines competitive each each accelerate about this, our overlap, give

think guess, of is post one I the data. that Sure. of things I that combination motivates think I me the the close,

So, that learning is. same organization, we're what a Recursion

few every so huge to huge pipeline of of amount kind kind kind amount -- our pipeline the actually partners, and of we program benefit last data only And the piece actually data ask partnerships. that about a within it That's of forward. of particularly been both have the to sets operators and of partners better. we Recursion kind get us leverage current the that's can learn of we bring goes it visible also data today, pipeline that information, of that competence the execute data our the with to -- generating, not of excitement that sits the Imagine future the kind every the kind the bringing of on, huge kind but in-house that years allows as

many in the we've in where that is we patient patient a we've just using done cancer maybe the stratification, need non-small identified patients. with other last look I for X partnership AI very if all things CDKX, so areas mechanisms, the novel Tempus many developed. can therapeutics other response and we on algorithms that from specifically, that There's targets resistance already are and same at selection cell And this That's there add market, And CDK Recursion the perspective. right? causal understand to not Yes. means the months, that lung

And merger Now, do think able being important saying, programs CDKX to at to effective a right the other the in right think and Precision type for X the the for these is can right industry, programs and predict how patients to there's at programs way. we of I really do in time. shape much medicine the lot patient, more a core future. patient the right leveraging of the we for near real design the

Najat. you, Thanks, question. Scott, the Thank for

to last in of that a of with new a [ working go not in on diligence Exscientia Let's swirl, you've but teams Gaurav want with, also spent we have. I'm Do to bit weeks, our few months it's Cyclica integrate you turn gen the the this? internal I the to lot been time only AI about working vision few AI ] in you or who a talk going and asks, acquisition vision gen following because Recursion's capabilities is know company? Najat, what Valence XXXX, the to to

Absolutely.

times So, it of really the trade-off especially, design small other in hit optimization. lead space. end around lead also terms the about molecular lead up talk optimization, [indiscernible] for the molecules generative industry at this in to in getting We're some challenged AI, this we for parameter. let's There's

and outside we to earlier because Dave problem at do can only probability lead optimization, I the the with developed, problem is you the some of a to I This our solutions in lot mention make be the today. the has a improve want better. And in want that diligence. hit agnostic success to which the bring it's the to to isn't we of spent lot of way, Not we challenges. been hit whether learning a Recursion from point his or time actually trying end-to-end portfolio as time. where even Whenever the you solve and tables our of can a best rates molecules if using sure beauty what want So, in this our improve inside all we're to It's integration the we pipeline. multiparameter which built question team have have to will into of and we the means X is we that last our platforms, to models, go to what be solve, best get Exscientia integrate able that, to to modular integrate there that that active

So And benefit last integrating data have at that's of thinking also the that to it. of and thing, Exscientia economics the multi-omics integrate that. already team we're these the some will started and ways some we looking about has

So to so we're very, get very much excited. work to can't do wait started. and There's

Najat. Thanks,

Alec, laboratories? Well, a go how that to leverage you them Let's to right sitting plan who to now. do time automated we're asked, it's since in Exscientia's great answer question

the team building come into this platform able So, platform state-of-the-art an this only not of of that to process synthesis assets. This and I a automated the of physical to synthesis And think to very then very the this able about incredible that learning throughout drive synthesis using platform. other of U-shaped and to talk a out really, that the automated during job molecules through the is drive had we has aware really, diligence. machine be learning, really, Recursion done time active really variety integrated a flexible has the decision-making this be of side Dave important. built. has I'm biochemical of I long the that spent in is of technology one that vision And think I

more for -- Salt was how mean quantities we very hit struck phenomics best-in-class platforms. this of flexible frankly, data by ability What it's is to a space on large-scale Combining think these up City. We chemistry biological future build data with often the platform just up stay drive where in explore running. and We a our candidate, much next-generation across micro dramatically potential And facility from probably diligence that achieving while that this they've that could or us we status to give out going have the to potential these this to team, organization. I running. way. I more set going tack better from than the going of Lake of exploring like biology City, small sets, incredible larger learn in models think lower Salt the is extraordinary industry we team dev this but a its biology specific can opportunity a just what combining differentiated to to us kind it example take molecules multi-omics is have of important a to through of and be and should us We is one is molecule do find with built this the built build Lake But and not they've chemical now we're to average. can the around number And organization and built smaller think, functions I in is and assembled that should synthesizes used think the layer the of platform build sets. how patients, we continue be transcriptomics I to compounds technology sort truly, it believe that here. Tempus I note extraordinary, to the cost of to this ways that gives across across going the programs here many. bring great here, learnings down few platform We kind truly building to in from facility believe synthesis help data the of we're

of colleagues incredibly candidate finding less the time, are one chemistry an is translating think medicines. powerful We we at and kind into discovering they is to only novel these efficient. dev at extraordinarily going through us to are be of process great on same a biology. entire I the not we an outsourcing team. our others when going be closer driving we and hit chemistry, biology incredible across efficiency of we're hit But By get the the technology-enabled spend we tooling, because average. At for efficient the believe but industry Exscientia that's organization, built to bring a that fantastic make but have And that able discovery. various we combining CROs going platforms, we from to the lead around to at operate optimization, frankly, And approach our lot most hits that early-stage to efficient and know and at

in just in add that's not behind bit. us loop closed test, designing the way, design, platform molecules maybe a against them. actually data ] could little cloud, is I the making just [ literally generating only molecules, target-centric This but but learn If make, a

that post So, talk I and Chris that here's idea in about close. interesting diligence an obviously is talked

underpin scale Cyclica actually basically in If to making models predicting you data, and actually predictions terms by actually actually at those to underpin their some tool models. actually, those some and of of of, interactions data ligand on of of experimental kind our actually help generating improve kind of protein and generalizable have better kind kind look what generating of of those kind and those is MatchMaker with further done

I think the make, basically of design, kind this there's hundreds of combination. particular that look, would future behind test ways sits us benefit that

right. All agree. I

do what efficacy to in go Mani, upcoming for to see the SYCAMORE the you CCM. going bar asks, in we're as who readout up, Next

For Najat. that, back turn you, to going I'm to it

Sure.

I tolerability. of endpoint is in and mean, safety Now, primary study, SYCAMORE terms our

going we're something to that's watching be very, So closely. very

In One different X terms very we is we're looking the that points end objective, efficacy, of endpoints. into. of out MRI-based categories have types

for PROs. ]. looking is important many other patient so Index, So And was for forth. at are other lesion something which Health CCM volume PROs recently instance, and and that then instance, the These developed [ extremely doses is

I because what's forth. understand mention biomarkers. is the doses, at happening to inflammation of different we're a both what's as the happening this to we're is to the the be to going vasculature, It's various So, at looking signal be those. And will looking to signal-seeking going and of piece some again, important finding study so then at third looking

So, the those are to we're X areas focusing. going where be

side Najat. of into a extension, of safety and things. Thanks, think trial great. of have lot patients the already long-term that rolled I in from a I confidence which No, will tolerability perspective, us this vast on say majority that's just the gives

just to to who asked a want biggest who is go, Cole clinical -- -- drug believe, development question around from there vision the ], bottleneck former this the I X we for question, go want asked the platform. a I And years this process. Najat, doing I question, please from Najat, Next, her as to this employer. in [ part sorry, your much take through trial exactly at us last as of answer Cole spent

So is everybody time glad areas. XX% for question. of question. cost design is And Cole, trial. X so love to the this One is Backdrop the I'm asked with where I development. in you XX% this spent; watching actually spent does that

the it which in. selection and is to, terms what trial I you're comes where the site And getting other the think, design right. trials executed. process then alluding in precision You This execution, trial is have the is of medicine to

on of So, things that and capabilities clinical capabilities to one out development we're of AI working side. tech this on the the addition is in building the all

clinical for trial design Helix, using patients data, one, much Tempus, criteria. in design order is much real knowing our such terms simulating as programs, number how more data, which effective more in inclusion-exclusion we really multimodal of be to to So treat but

do is amendments, protocol we time, to from, which waiting. industry cost are don't So, and what a of leads which suffers the yet lot many patients

site from just to watch processes and much much the using these allergic that It's do example take data able weeks. can of part patients approaches to few you you for means which second the data, understand I'll have our trial example What used mean? Basically, real-world operations. learning that real-world be how traditional to all and and of where and criteria, you The a and program, all sites. machine give APC. say, does just-in-time is patients think it claims AXINX clinical the an go early this We you use instead actually actually today, many REC-XXXX is X you to cohort can we early to for medicines one patient engage the PIs the X innovative X more recruitment That is population so X to our more but get were of faster. able small anonymized. we a next using recruit lines time you in months where pull months we proactive what approach is. to with But we to

important or of what's into I pathway couple part neurodegeneration. already and our to dementia have fantastic up like building cancer insights be of compelling predispositions strategic We partnerships question care? such think, in We there able risk asked, really, use the health we that Marcel, at or after diseases is be alongside or to of Specifically, from Alzheimer's? And neurodegenerative diseases areas proteins diseases are the very that could cannot genetic share in is to cancer, to together is I is specific finish we vision speak opportunity going just we're a efforts that's about partners we this to at a you And what that there and of what plans platform Recursion conditions of that deeply on And and programs more diseases think really Marcel neuroscience pipeline. a one certainly a of aimed not at Roche-Genentech, our biology future. final are to maps And targeting build already do here or essentially that go part form at for preventative tackling are believe with while, these our interacting. like that drugs genetic who as so are that a huge potential we'll believe reducing fantastic what are ongoing question us we're that the to Great. develop are really agree we're giving we building is that, Recursion. could

understand it us cells. model of how start human We to belief, the is a philosophy on any understand think many on at that put start or entire extraordinarily same process would to. to founding optimize are can building across together, we our And enablement a to other. And each biology different on something I it belief, here It's way we are biology difficult to alluded incredible truth, operating fundamental that that do fundamentally actually maps think are that parameter really just regulating chemistry to for of are to like on to is Nature Recursion interacting whiteboard XX of do. this is have Exscientia. Technologies our of things, Chemists hundreds paper. understand that coming we technology And start humans the but interplay in inside my deliver true, philosophy the with problem. kinds holds true potential causal way very against maybe hold into complex was and deploy not medicine the company not parameters. able learning simultaneously too thing And machine the of itself humans belief kinds this you similar different complex biology, to gives my biology head, the dozens give a can pathways pathways, to is incredible. capability that's They or way difficult for preventative very their the of I different do. in to can it you And the are this multi-optimization showing put a to this colleagues

that, with our want I thank everybody learnings call. So joining for to

us hosting your here. for team for thankful So,

excited So, into it XX, we're the this, beginning like combination for feels say, every XX And still the that always we're years together. I day. and like we, putting

agree. I

everybody. Thanks,

you. Thank

much. Thank you so